The Proteome Landscape of Human Placentas for Monochorionic Twins with Selective Intrauterine Growth Restriction

- $\overline{4}$
- 5 Xin-Lu Meng^{1,#}, Peng-Bo Yuan^{1,#}, Xue-Ju Wang¹, Jing Hang^{2,3,4,5}, Xiao-Ming Shi¹,
- 6 Yang-Yu Zhao^{1,*}, Yuan Wei^{1,*}
-
- *1 Department of Obstetrics and Gynecology, Peking University Third Hospital,*
- *Beijing 100191, China*
- ² Center for Reproductive Medicine, Department of Obstetrics and Gynecology,
- *Peking University Third Hospital, Beijing 100191, China*
- *3 Key Laboratory of Assisted Reproduction, Ministry of Education, Beijing 100191,*
- *China*
- *4 Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproduction,*
- *Beijing 100191, China*
- *5 National Clinical Research Center for Obstetrics and Gynecology, Beijing 100191,*
- *China*
-
- $*$ Equal contribution.
- 20° Corresponding authors.
- 21 E-mail: weiyuanbysy@163.com (Wei Y), zhaoyangyu@bjmu.edu.cn (Zhao YY).
22
-

²³**Abstract**

²⁴In perinatal medicine, intrauterine growth restriction (IUGR) is one of the greatest 25 challenges. The etiology of IUGR is multifactorial, but most cases are thought to arise 26 from placental insufficiency. However, identifying the placental cause of IUGR can 27 be difficult due to numerous confounding factors. Selective IUGR (sIUGR) would be 28 a good model to investigate how impaired placentation affects fetal development, as 29 the growth discordance between monochorionic twins cannot be explained by 30 confounding genetic or maternal factors. Herein we constructed and analyzed the 31 placental proteomic profiles of IUGR twins and the normal cotwins. Specifically, we 32 identified a total of 5481 proteins and 233 differentially expressed proteins (DEPs), 33 including 57 upregulated and 176 downregulated DEPs in IUGR twins. Bioinformatic 34 analysis indicates that these DEPs are mainly associated with cardiovascular system 35 development and function, organismal survival, and organismal development. Notably, ³⁶34 DEPs are significantly enriched in angiogenesis, and diminished placental 37 angiogenesis in IUGR twins has been further elaborately confirmed. Moreover, we ³⁸found decreased expression of *metadherin* (*MTDH*) in placentas for IUGR twins and 39 demonstrated that *MTDH* contributes to placental angiogenesis and fetal growth *in* ⁴⁰*vitro*. Collectively, our findings reveal the comprehensive proteomic signature of 41 placentas for sIUGR twins, and the DEPs identified may provide in-depth insights 42 into pathogenesis of placental dysfunction and subsequent impaired fetal growth.

43

⁴⁴**KEYWORDS:** Selective intrauterine growth restriction; Placenta; Proteome; ⁴⁵Angiogenesis; *Metadherin*

46

⁴⁷**Introduction**

⁴⁸Intrauterine growth restriction (IUGR), which refers to the inability of the fetus to 49 reach its full growth potential, is among the most common pregnancy complications ⁵⁰and affects 7% of pregnancies worldwide [1]. Besides contributing to significant 51 perinatal and pediatric morbidity and mortality, it can also raise the risk of developing ⁵²metabolic, cardiovascular, and respiratory disorders later in life [2,3]. Despite the ⁵³involvement of multiple factors, placental insufficiency has been reported as a major 54 cause of IUGR [4,5]. Placental insufficiency refers to a process of progressive 55 deterioration of placental function. It reduces transplacental oxygen and nutrients 56 transfer to the growing fetus, and ultimately limits placental performance during 57 pregnancy [6,7]. However, identifying the molecular mechanisms underlying 58 pathogenesis of placental insufficiency is challenging due to the interference of 59 numerous maternal and genetic confounding factors.

60 Selective IUGR (sIUGR) is a unique complication of monochorionic (MC) twins in which one twin is an IUGR fetus and the cotwin grows normally. An estimated 10%–15% of MC pregnancies suffer from it [8]. Several studies have extensively investigated the development of sIUGR at the gross histopathological level and have 64 shown that sIUGR is associated with a remarkable discordance of placental sharing wherein the IUGR twin is supported by a smaller portion of the placenta. Also, a higher incidence of abnormal cord insertion occurs in the smaller fetuses [9,10]. 67 Additionally, the terminal branch levels of the placental artery and vein were significantly lower in the IUGR twins [11]. Together, these morphological alterations suggest placental insufficiency and impaired blood perfusion to the fetus in sIUGR. The two fetuses harbor an identical genotype and share the same maternal environment. Thus, sIUGR twins would provide an ideal model to investigate the underlying mechanisms of placental insufficiency by using the healthy cotwin as an internal control to eliminate confounding maternal and genetic factors and to ensure the same gestational age. Recent studies have found that dysregulation of several angiogenesis-related genes, such as *endoglin* and *fms-like tyrosine kinase 1* (*FLT1*),

⁷⁶may contribute to the development of sIUGR [12–14]. The *hypoxia inducible* ⁷⁷*factor-1a* (*HIF1A*) mRNA levels, as well as 8-hydroxydeoxyguanosine (8-OHdG) and ⁷⁸malondialdehyde (MDA), both biomarkers of oxidative stress, have been 79 demonstrated to be significantly upregulated in IUGR twin placentas, suggesting that 80 oxidative stress might participate in the pathogenesis of sIUGR [15]. In other studies, 81 abnormal placental epigenetic modification, such as altered imprinted genes and DNA 82 methylation, has been found to cause sIUGR [16,17]. However, a systematic placental 83 proteomic profile linked with the functional analysis of clinical sIUGR is still absent.

⁸⁴In this study, we systematically investigated the placental proteome differences 85 between IUGR twins and the normal cotwins utilizing tandem mass tag (TMT)-based 86 technology. In total, we identified 5481 proteins and 233 differentially expressed 87 proteins (DEPs), of which 57 were upregulated and 176 were downregulated. 88 Bioinformatic analysis by ingenuity pathway analysis (IPA) revealed that these DEPs 89 were most significantly enriched in cardiovascular system development and function, ⁹⁰as well as organismal survival and organismal development. Notably, 34 DEPs were ⁹¹associated with the biological process of angiogenesis, and we found that 92 angiogenesis was significantly impaired in IUGR twin placentas. The differential ⁹³expression of *ephrin B2* (*EFNB2*), *vimentin* (*VIM*) and *methionyl aminopeptidase 2* ⁹⁴(*METAP2*), which are essential in placental angiogenesis, was validated by PCR and ⁹⁵immunohistochemistry analysis. In addition, we found that *metadherin* (*MTDH*) was ⁹⁶significantly downregulated in IUGR twin placentas. Knockdown of *MTDH* in human ⁹⁷umbilical vein endothelial cells (HUVECs) obviously inhibited the proliferation, ⁹⁸migration, tube formation, and spheroid sprouting by affecting numerous genes and ⁹⁹biological processes. In brief, our study is the first comprehensive analysis of the 100 placental proteomic profile in sIUGR twins and may offer deeper insights into the 101 molecular mechanisms of IUGR.

¹⁰³**Results**

¹⁰⁴**Clinical characteristics**

¹⁰⁵To identify novel candidate molecules for sIUGR, we harvested 12 placental samples 106 from six sIUGR twin pairs and performed TMT-based comparative proteomic 107 analysis. sIUGR twins, which share the maternal environment and harbor an identical 108 genotype, provide an ideal model for investigating the association between placental 109 development and fetal growth. The demographics and clinical characteristics of the 110 twin pregnancies in this study are presented in Table S1 and Figure S1A–D. All twins 111 were delivered alive by cesarean section at a mean gestational age of 32.3 ± 1.2 weeks. ¹¹²The birth weight of the IUGR twins was, on average, 628 grams lower than that of 113 their healthy cotwins $(P = 0.0004)$, with relative birth weight discordance ranging ¹¹⁴from 25.2% to 48.0%. None of the study population had twin-to-twin transfusion ¹¹⁵syndrome, fetal malformations, and maternal complications such as preeclampsia or ¹¹⁶diabetes mellitus. In addition, IUGR twin placentas exhibited more pathological 117 abnormalities, including distal villous hypoplasia, intervillous fibrin deposition, 118 increased syncytial knots, and abnormal cord insertion. (Figure S1E–I).

Comparative proteomic analysis identifies 233 DEPs in IUGR twin placentas 120 To comprehensively profile the global placental proteomic changes between IU

¹²⁰To comprehensively profile the global placental proteomic changes between IUGR 121 twins and normal cotwins, we applied a high-accuracy quantitative proteomic ¹²²approach to analyze protein expression (**Figure 1**A). A total of 12 samples from 6 123 pairs of sIUGR twins were processed in the same experimental period. After protein 124 extraction, reduction, alkylation, and digestion, each 3 pairs of sIUGR twins were 125 labeled with one set of six-plex TMT reagent (group 1: TMT 126, 127, and 128 for 126 normal cotwin 1, 2, and 3; TMT 129, 130, and 131 for IUGR twin 1, 2, and 3 127 respectively; group 2: TMT 126, 127, and 128 for normal cotwin 4, 5, and 6; TMT ¹²⁸129, 130, and 131 for IUGR twin 4, 5, and 6 respectively). Six isobaric labeled 129 samples within the same set were mixed together and then separated into 10 fractions 130 by high pH reversed-phase liquid chromatography (RPLC). All 20 fractions from two ¹³¹TMT sets were subjected sequentially to liquid chromatography tandem mass 132 spectrometry (LC-MS/MS). MS data were then collected and analyzed for protein 133 identification and quantification. Details on MS data analysis were presented in the ¹³⁴Methods section. Specifically, we identified a total of 5481 nonredundant proteins in

¹³⁵sIUGR twin placentas (Table S2). A histogram plot revealed the fold change (FC) 136 distribution of all identified proteins (Figure 1B). The distribution of statistical 137 significance (−log₁₀ transformed *P* value) and degree of change (log₂ transformed FC) 138 for all identified proteins were presented in the volcano plot (Figure 1C). Using a 139 combination of $P < 0.05$ and $|FC| > 1.3$, 233 proteins displayed significant differential 140 expression in IUGR twin placentas compared to the normal cotwin placentas. Of these, ¹⁴¹57 DEPs were upregulated and 176 DEPs were downregulated (Table S3). ¹⁴²Unsupervised hierarchical clustering of the DEPs revealed good separation between 143 the two groups (Figure 1D).

¹⁴⁴To deepen the biological insights into these DEPs, we utilized IPA software for 145 bioinformatics analysis. The core biofunction analysis of these DEPs was divided into 146 three categories. In "physiological system development and function" category, the ¹⁴⁷most significantly enriched item was "cardiovascular system development and 148 function", which involved 52 DEPs. The other two main enriched subcategories were 149 "organismal survival" (number of DEPs in this function $[n] = 66$) and "organismal" 150 development" $(n = 71)$ (Figure 1E; Table S4). In addition, in "molecular and cellular 151 function" category, the top three enriched functions included "cell death and survival", ¹⁵²"lipid metabolism", and "molecular transport" (Figure S2A; Table S4). For "diseases 153 and disorders", the DEPs were significantly related to "endocrine system disorders", ¹⁵⁴"gastrointestinal disease", and "metabolic disease" (Figure S2B; Table S4). ¹⁵⁵Additionally, IPA canonical pathway analysis identified oxidative phosphorylation, 156 mitochondrial dysfunction, and the Sirtuin signaling pathway as the top three 157 pathways that might be potentially affected in IUGR twin placentas (Figure S2C).

¹⁵⁸**Angiogenesis is significantly impaired in IUGR twin placentas**

159 Among the 52 DEPs involved in "cardiovascular system development and function", 160 34 DEPs were enriched in the biological process of angiogenesis encompassed in this 161 biofunction, and the state of angiogenesis was predicted to be suppressed by IPA ¹⁶²(**Figure 2**A). Placental angiogenesis is crucial to villous development and placental ¹⁶³function. Any impairment in placental angiogenesis can lead to poor placentation, ¹⁶⁴decreased blood flow to the fetus, and various pregnancy complications [18]. To

¹⁶⁵confirm whether angiogenesis was altered in IUGR twin placentas, we assessed the ¹⁶⁶microvessel density (MVD) and vascular area density per sample following 167 immunostaining of CD34 as an endothelial cell marker. A significant decrease in ¹⁶⁸MVD was present in IUGR twin placentas, while the vascular area density was also 169 significantly lower in IUGR twin placentas than in the normal cotwins (Figure 2B–D). 170 Taken together, these data suggested that impaired placental angiogenesis in IUGR 171 twins might be responsible for the development of sIUGR. To further validate the ¹⁷²proteomic results, we selected 3 markers (*EFNB2*, *VIM*, and *METAP2*) for 173 immunohistochemistry analysis. The 3 markers were reported to play essential roles 174 in placental angiogenesis and fetal development $[19–21]$. As shown in Figure 2E–H, 175 the intensity of VIM, EFNB2, and METAP2 immunoreactivity was significantly 176 lower in IUGR twin placentas than in normal cotwins, which was in line with TMT 177 proteomic results. Additionally, we performed qRT-PCR to explore their expression ¹⁷⁸changes at mRNA level. Similar to the proteomic data, *VIM*, *EFNB2*, and *METAP2* ¹⁷⁹mRNA expression levels were significantly downregulated in IUGR twin placentas 180 (Figure 2I–K).

¹⁸¹*MTDH* **silencing inhibits HUVEC proliferation and migration**

Among the 34 DEPs related to angiogenesis, we also observed a significant decrease 183 in *MTDH* expression in IUGR twin placentas (**Figure 3**A–C). There is evidence that *MTDH* participates in tumor angiogenesis [22,23], while its role in placental angiogenesis remains unclear. During placental angiogenesis, endothelial cells 186 undergo proliferative, migratory, and morphological events to form a vessel network. To investigate the causality between endothelial *MTDH* deficiency and sIUGR 188 development, the role of *MTDH* in the proliferation and migration of HUVECs was 189 explored. HUVECs were transfected with negative control siRNA (si-NC) and siRNA against *MTDH* (si-*MTDH*). Transfection with si-*MTDH* markedly decreased *MTDH* mRNA and protein levels (Figure 3D–F). The proliferation and migration abilities of HUVECs were examined using an electrical impedance-based tool, the xCELLigence® real-time cell analysis (RTCA) system, which enables continuous monitoring of cell behaviors and allows for real-time assessment of multiple cell

195 functions. For the proliferation assay, cells treated with si-NC or si-*MTDH* were 196 seeded in the wells of an E-plate. Cells were cultured for 60 h, and the si-*MTDH* 197 group exhibited a significant reduction in proliferation ability (Figure 3G). Cell 198 migration was assessed using a CIM-16 plate with upper and lower chambers in each 199 well. The results revealed that *MTDH* interference obviously decreased HUVEC ²⁰⁰migration ability compared with that of control cells (Figure 3H). To further confirm 201 the effect of *MTDH* deficiency on HUVEC migration in the horizontal direction, we 202 performed a wound healing assay. As expected, the wound in the 203 si-*MTDH*-transfected cell culture healed more slowly than that of the control group ²⁰⁴(Figure 3I, J). In summary, these findings demonstrated that *MTDH* is vital to ²⁰⁵HUVECs proliferation and migration.

²⁰⁶**Knockdown of** *MTDH* **inhibits tube formation and spheroid sprouting in** ²⁰⁷**HUVECs**

²⁰⁸To further determine *MTDH*'s effect on placental angiogenesis, the 2-dimensional (2D) 209 tube formation assay and 3-dimensional (3D) spheroid sprouting assay were 210 conducted using HUVECs. As shown in **Figure 4**A, si-NC-transfected HUVECs 211 could form capillary-like structures in a few hours on Matrigel, while the tube 212 formation capacity was perturbed in the si-*MTDH* group. *MTDH* deficiency distinctly 213 impaired the number and area of tubes, the total tube length, as well as the number of 214 branching points (Figure 4B–E). Similarly, when embedded in 3D collagen I gels, 215 spheroids composed of si-NC-transfected HUVECs retained the ability to produce 216 capillary-like outgrowths, while only a few sprouts were formed in *MTDH*-depleted ²¹⁷HUVEC spheroids (Figure 4F). Compared to the control cells, the si-*MTDH* HUVECs 218 exhibited a significant reduction in cumulative sprout length (Figure 4G). Accordingly, 219 these data suggest that downregulation of *MTDH* inhibits placental angiogenesis.

²²⁰*MTDH* **is required in placental development and fetal growth**

221 To verify whether *MTDH* is required in placental and fetal development, we knocked 222 down *MTDH* in HUVECs and performed RNA-seq analysis. Both the control and 223 si-*MTDH* groups had three biological replicates each. The correlation analysis based 224 on the overall RNA-seq data for each sample pair showed that the correlation

225 coefficient between intra-group samples was higher than that between inter-group 226 samples, indicating that samples within groups had strong resemblance in terms of 227 transcription pattern and the biological experimental operations were reliable and 228 reproducible, while the gene expression changed following MTDH interference. ²²⁹(**Figure 5**A). The top 50 protein-coding genes with significantly differential 230 expression (adjusted $P < 0.05$) were selected as candidates for further analysis (Table ²³¹S5). Among the 50 genes, 29 were upregulated and 21 were downregulated in the 232 si-*MTDH* group. The expression profiles of the 50 genes are presented in a heatmap ²³³(Figure 5B). Further functional enrichment analysis revealed that 50 candidate genes ²³⁴were associated with various biological processes, such as defense responses, ²³⁵apoptotic processes, actin filament organization, negative regulation of cell 236 proliferation, and angiogenesis (Figure 5C). The interaction network of the 50 237 candidates is presented in Figure 5D.

238 Among the 50 candidates, we found quite a few genes previously reported to be 239 implicated in placental dysfunction and fetal growth restriction, including *PSG3* (upregulation of *PSG3* in both maternal blood and IUGR placenta) [24,25], *CSF2* (*Csf2*-deficient *mice* exhibit placental insufficiency and fetal growth retardation) [26,27], *THSD7A* (higher expression of *THSD7A* is associated with low birth weight) [28], *CYP1B1* (lower methylation levels of *CYP1B1* are found in preterm delivery with reduced fetal growth) [29], and *PLCL1* (double-knockout *mice* for *Plcl1* and *Plcl2* exhibit reduced litter events and litter size) [30]. These results further provide 246 support for the validity of our results. Interestingly, we also found several unreported genes that may affect placental development and fetal growth, such as *IFITM2*, *TMSB15A*, and *WAS*. These findings may help further the discovery of potential 249 biomarkers and therapeutic targets.

²⁵¹**Discussion**

²⁵²Despite advances in perinatal care, IUGR remains a challenging problem faced by 253 obstetricians worldwide. Placental insufficiency and subsequent undernutrition and

²⁵⁴hypoxia are considered to be the ultimate pathomechanisms that disturb fetal growth ²⁵⁵[31]. However, the molecular regulatory mechanisms of IUGR have not been fully 256 elucidated due to genetic and maternal heterogeneity. In monochorionic twin 257 pregnancy, the IUGR twin and the normal cotwin have an identical genotype and 258 develop in the same uterus, making it an excellent model to investigate placental 259 disorders [32]. Proteins, which act as the ultimate executors of gene function, are vital 260 players within organisms in terms of functionality and structure [33]. Thus, 261 investigating the molecular basis for IUGR at the protein level is of paramount 262 importance to shed light on its clinical diagnosis and treatment. Based on the above 263 information, we sought to construct a comprehensive profile of the placental DEPs by 264 taking advantage of sIUGR twins. In this work, we performed TMT-based 265 comparative proteomic studies using placental samples of six sIUGR twin pairs from 266 the clinic. A total of 5481 unique proteins with high confidence were detected in 267 human placental tissues. Therein, 233 proteins were identified as DEPs between ²⁶⁸IUGR twin and normal cotwin placentas, with 57 upregulated and 176 downregulated. 269 In the current work, numerous proteins relevant to embryonic development were 270 found to be dysregulated in IUGR twin placentas. As the interface of interaction and 271 communication between mother and fetus, the placenta is essential to embryo 272 development and, in particular, to fetal growth [34]. The aberrant expression of these 273 proteins in IUGR twin placentas implies that they may play key roles in impairing 274 fetal growth potential. In addition, a set of proteins that can modulate lipid 275 metabolism were detected in our study. Over the past few decades, lipid metabolism 276 during pregnancy has been highlighted as essential not only for optimal placental ²⁷⁷development and function but also for proper intrauterine growth of the fetus [35]. ²⁷⁸Disrupted lipid metabolism may contribute to placental insufficiency and suboptimal 279 fetal growth, which is consistent with previous discoveries in singleton IUGR cases ²⁸⁰[36,37]. In addition, proteins that are key players in molecular transport appeared 281 prominently among the top functional terms. In fact, the formation of an efficient 282 transport interface is the essence of the placenta, which allows the growing fetus to ²⁸³fulfill its developmental demands from maternal circulation [34]. Alterations in

284 nutrient transporter expression have also been evidenced in IUGR placentas [38,39].

285 Notably, we found that 34 DEPs were implicated in angiogenesis. Adequate 286 angiogenesis ensures that placentas develop as highly vascularized organs, thereby 287 supporting the blood flow required for fetal growth [40]. Aberrant placental 288 vasculature has been identified in nearly all human pregnancy complications, further 289 confirming the importance of placental angiogenesis for normal pregnancy [41]. A 290 previous study discovered significantly decreased villus vascular density in placentas 291 of singleton IUGR [42]. Our results also confirmed that placental MVD and vascular 292 area density were significantly lower in smaller fetuses. These results together suggest 293 that impairment of placental angiogenesis may play key roles in the incidence and 294 development of IUGR. *MTDH*, also known as *AEG-1*, is implicated as an oncogene ²⁹⁵[43,44]. According to our findings, *MTDH* was significantly downregulated in IUGR 296 twin placentas and located in intravillous capillary endothelial cells. In addition, we 297 verified that the function of *MTDH* is critical in placental angiogenesis, indicating that ²⁹⁸decreased expression of *MTDH* may contribute to the pathogenesis of placental 299 dysfunction and fetal growth retardation. While our understanding of the molecular ³⁰⁰mechanisms of IUGR has advanced significantly over the past few decades, there are 301 currently no reliable diagnostic biomarkers or targeted therapies available for this ³⁰²disease in clinical practice [45,46]. Translational application of the candidate targets 303 identified in singleton IUGR pregnancies is very limited, probably mainly due to the ³⁰⁴heterogeneity of the samples in these studies. Thus, MTDH identified in our ³⁰⁵investigation using sIUGR twins may serve as a potential biomarker for early 306 prediction and accurate diagnosis of IUGR, as well as a novel target for future 307 treatment. In summary, our findings comprehensively described the proteomic ³⁰⁸landscape of sIUGR twin placentas, which may provide reliable resources for ³⁰⁹mechanistic studies of the core regulators involved in placental dysfunction and fetal 310 growth restriction.

311

³¹²**Materials and methods**

³¹³**Patients and clinical specimen collection**

³¹⁴Placental samples from 6 sIUGR twins were collected at Peking University Third ³¹⁵Hospital. Ultrasonography at 11–14 weeks was conducted to determine the 316 chorionicity, and postnatal placental examination was used to confirm it. sIUGR 317 refers to a monochorionic twin in which the estimated fetal weight (EFW) of one 318 fetus is lower than 10th percentile while the cotwin's is normal and the intertwin EFW 319 discordance is more than 25%. EFW was calculated based on Hadlock formula [47]. ³²⁰EFW discordance was calculated with this formula: (normal cotwin EFW−IUGR twin ³²¹EFW)/normal cotwin EFW. All participants underwent cesarean delivery, and the 322 samples were collected within 30 min. Samples were obtained from the maternal side 323 of the placental lobules within 2 cm of each umbilical cord insertion site, aiming to 324 reduce possible bias caused by the regional variations in placental gene expression 325 associated with the sampling sites [48,49]. The placental biopsies were excised in 326 areas free of macroscopic lesions of calcification or infarction after removing the ³²⁷maternal deciduas and fetal membranes. The biopsy was washed in PBS for blood 328 removal. A portion of the sample was stored at −80°C after freezing in liquid nitrogen. ³²⁹The rest was fixed in 10% formalin solution followed by embedding in paraffin.

³³⁰**Protein extraction, digestion, and TMT labeling**

331 Placental tissues were lysed using 7 M urea with 1% (w/v) dithiothreitol (DTT), 2 M 332 thiourea, and 1% (v/v) protease inhibitor cocktail. Equal amounts of protein (100) ³³³µg/sample) were used for subsequent processing. 1 M DTT was used for peptide 334 reduction at 56° C for 30 min and 1 M iodoacetamide for alkylation at room 335 temperature for 30 min in darkness. Samples were diluted with 25 mM (pH 8.2) 336 Tris-HCl and 0.1 M CaCl2 until the final concentration of urea was 1 mM. Trypsin ³³⁷(Catalog No. V5111, Promega, Madison, WI) was used to digest proteins for 12 h. ³³⁸The resulting peptides were desalted on Sep-Pak C18 columns (Waters, Altrincham 339 Road, Wilmslow, UK), and then labeled with two sets of six-plex TMT reagents ³⁴⁰(Catalog No. 90062, Thermo Fisher Scientific, Waltham, MA). Each 6 isobaric 341 labeled samples within the same set were combined and vacuum dried for further 342 analysis.

³⁴³**LC-MS/MS**

³⁴⁴The peptide mixture was separated into 10 fractions by high pH RPLC using BEH 345 C18 columns (1.7 µm, 1.0 mm \times 150 mm) attached to the H-Class System (Waters). ³⁴⁶The second-dimensional liquid chromatography separation of the peptides was 347 conducted on the EkspertTM nano LC 415 instrument (AB Sciex, Toronto, Canada). ³⁴⁸The peptides were eluted using 2% acetonitrile with 0.1% formic acid as buffer A and ³⁴⁹98% acetonitrile with 0.1% formic acid as buffer B with a gradient of 100 min. The ³⁵⁰eluted peptides were subsequently analyzed using TripleTOF 5600+ mass 351 spectrometer (AB Sciex). Data were obtained in positive ion mode. For TOF-MS scan, 352 the mass range was set as $350-1500$ ^{m/z}. The MS/MS scan was carried out with a 353 mass range of $100-1500$ m/z .

³⁵⁴**Data analysis**

355 The raw data were analyzed by using the MaxQuant software (Version 1.5.2.8) [50] ³⁵⁶and the human UniProt reference protein sequences [51] to generate initial ³⁵⁷spectra-peptide matches and quantification values. The search was performed with the 358 following parameters: enzyme, trypsin/p; max missed cleavages, 2; 0.1 Da for first 359 search mass tolerance; 0.01 Da for main search mass tolerance; variable modifications, 360 acetylation (N-term) and oxidation (M); fixed modification, carbamidomethyl (C). 361 Protein identification requires at least one unique peptide. False discovery rate (FDR) 362 was 0.05 for both peptide and protein identification. Then, the MaxQuant results were ³⁶³further processed by the MaxReport software [52] to correct and optimize the ³⁶⁴quantitative results. In brief, the reporting intensity of each isobaric label was 365 corrected by an impurity correction matrix. Additionally, each label (sample) was 366 normalized by the total intensity. Then, the relative protein expressions were 367 calculated by the Libra algorithm [53]. Finally, DEPs were determined by $P < 0.05$ 368 and $|FC| > 1.3$. The MaxReport quantification workflow was also successfully tested 369 by using a benchmark dataset (PXD000001) to quantify the spiked reference proteins. ³⁷⁰Additionally, all of the samples were harvested and processed in the same 371 experimental period. Due to the limited number of TMT labels, these samples were ³⁷²labeled separately and loaded into the mass spectrometer in a sequential process.

³⁷³Comparison of the average intensities and unique peptides between the two six-plex ³⁷⁴TMT experiments indicated that there was a minor batch effect between the two 375 groups, as the Pearson correlation coefficient values for intensities and peptides were ³⁷⁶0.96 and 0.98, respectively. Considering only two sequential batches in this study, we ³⁷⁷did not perform such correction. The global protein expression patterns of sIUGR 378 twin placentas were illustrated using histograms and volcano plots in the R package ³⁷⁹(version 3.5.2). Hierarchical cluster analysis of the DEPs was performed with MeV 380 software (version 4.9.0). We used IPA software (QIAGEN, Redwood City, CA) to 381 identify the biofunctions that were significantly associated with the DEPs. ³⁸²Specifically, the list of DEPs, containing gene symbols, fold changes and *P* values, ³⁸³was uploaded into IPA software for core analysis. The core analysis included ³⁸⁴enrichment of diseases and functions, canonical pathways, and networks. The core 385 analysis was conducted with the setting of direct and indirect relationships between 386 focused genes based on the human section of "Ingenuity Knowledge Base", which ³⁸⁷was a manually curated database of biological interactions and functional annotations.

³⁸⁸**Immunohistochemistry**

³⁸⁹After deparaffinization, antigen retrieval and endogenous peroxide blocking, the 390 sections (5 µm in thickness) were incubated with primary anti-CD34 antibody ³⁹¹(Catalog No. ZM-0046, ZSGB-BIO, Beijing, China), anti-EFNB2 antibody (1:50; ³⁹²Catalog No. HPA008999, Atlas Antibodies, Bromma, Sweden), anti-METAP2 393 antibody (1:3000; Catalog No. HPA019095, Atlas Antibodies), anti-VIM antibody ³⁹⁴(Catalog No. ZM-0260, ZSGB-BIO) and anti-MTDH antibody (1:150; Catalog No. ³⁹⁵ab124789, Abcam, Cambridge, UK). After incubating with secondary antibodies, the 396 sections were stained with diaminobenzidine solution (Catalog No. ZLI-9018, ³⁹⁷ZSGB-BIO). The expression level of the target genes was assessed with Image-Pro 398 Plus (Media Cybernetics, Rockville, MD).

³⁹⁹**MVD and vascular area density**

⁴⁰⁰Using CD34 as an endothelial cell marker, the MVD was used to evaluate placental 401 angiogenesis by measuring the immunostaining of CD34 in placental sections. Briefly, 402 the number of CD34-positive vessels was counted under a magnification of $400\times$ in 5

⁴⁰³nonconsecutive fields by two observers who were blinded to the control and case 404 groups. The mean value of the 5 fields was expressed as the MVD. The vascular area 405 density was evaluated as follows: 5 images per slide with a magnification of \times 200 ⁴⁰⁶were captured by NanoZoomer-SQ (Catalog No. C13140-01, Hamamatsu, Shizuoka, 407 Japan) and NDP.view2 software (Hamamatsu). Image-Pro Plus (Media Cybernetics) ⁴⁰⁸was used for measurement of the vascular area and the villous area. The mean of the 409 percentage of vascular area in villous area in 5 images was defined as the vascular 410 area density.

⁴¹¹**RNA extraction and qRT-PCR**

⁴¹²RNA was extracted using TRIzol (Catalog No. 15596018, Thermo Fisher Scientific), 413 and then reverse-transcribed into cDNA. $qRT-PCR$ was conducted with the SYBR[™] ⁴¹⁴Green Master Mix reagent (Catalog No. A25742, Thermo Fisher Scientific). Internal ⁴¹⁵reference gene was *glyceraldehyde-3-phosphate dehydrogenase* (*GAPDH*). All 416 experiments were replicated three times independently. Sangon Biotech Corporation 417 (Shanghai, China) supplied the primers (Table S6).

⁴¹⁸**Cell culture**

⁴¹⁹Immortalized HUVECs were a generous gift from Peking University Third Hospital 420 Medical Research Center. HUVECs were cultured in DMEM/F-12 medium (Catalog ⁴²¹No. C11330500BT, Thermo Fisher Scientific) containing 1% penicillin/streptomycin ⁴²²(Catalog No. V900929, Sigma-Aldrich, St. Louis, MO) as well as 10% fetal bovine 423 serum (FBS) (Catalog No. 10099141, Thermo Fisher Scientific) at 37° C with 5% CO₂. 424 HUVECs were authenticated with short tandem repeat analysis.

⁴²⁵**Cell transfection**

Transient transfection of HUVECs with siRNA was performed at 70% confluence in six-well plates using Lipofectamine 3000 (Catalog No. L3000015, Thermo Fisher 428 Scientific). *MTDH* siRNA sequences were as follows: sense, (5'-3') GGAACCAAUUCCUGAUGAUTT; antisense (5'–3') AUCAUCAGGAAUUGGUUCCTT. The siRNA was synthesized by GenePharma (Shanghai, China).

-
- ⁴³²**Western blotting**

⁴³³Proteins (20 mg for each sample) were electrophoresed on 8% SDS-PAGE gels and 434 then transferred to polyvinylidene fluoride membranes (Catalog No. IPVH00010, 435 Millipore Bedford, MA). The membranes were blocked in 5% nonfat dry milk 436 followed by incubating with anti-MTDH antibody $(1:10,000)$; Catalog No. ab124789, ⁴³⁷Abcam) and anti-GAPDH antibody (1:5000; Catalog No. ab8245, Abcam) overnight 438 at 4° C. After incubating with secondary antibodies, the bands were revealed with an ⁴³⁹enhanced ECL Kit (Catalog No. BF06053-500, Biodragon, Beijing, China) and ⁴⁴⁰analyzed by ImageJ (National Institutes of Health, NIH) using GAPDH as the loading 441 control.

⁴⁴²**Real-time cell proliferation and migration assays**

⁴⁴³The RTCA analyzer (ACEA Biosciences, San Diego, CA) was used to examine cell ⁴⁴⁴proliferation and migration abilities. The cell proliferation assay was carried out on 445 the E-plate with each well consisting of $5\Box \times \Box 10^3$ cells treated with si-*MTDH* or 446 si-NC. The impedance of each well, expressed as the cell index (CI), was ⁴⁴⁷automatically measured every 30 min for 60 h. The migration assay was performed in 448 a CIM-16 plate. A total of 2×10^4 transfected cells were seeded into the upper 449 chamber with serum-free medium, while it was complete medium in the lower 450 chamber. Scans were run with sweeps every 15 min for 60 h. The impendence of each 451 well was also represented by the CI.

⁴⁵²**Wound healing assay**

153 In 6-well plates, 5×10^5 HUVECs transfected with either si-*MTDH* or si-NC were ⁴⁵⁴seeded per well. When cells reached confluence, scratches were made with 200-µl 455 pipette tips. Afterwards, serum-free medium was used for cell culture, and images 456 were captured every 12 h for a total of 24 h. The NIH ImageJ software was applied to 457 analyze the cell migration distance.

⁴⁵⁸**Tube formation assay**

⁴⁵⁹In 96-well plates, 60 µl of Matrigel (Catalog No. 356234, BD Biosciences, Bedford, ⁴⁶⁰MA) was placed in each well, which was then solidified at 37°C for 30 min. 461 Transfected HUVECs $(2 \times 10^4/\text{well})$ were seeded into Matrigel-coated wells and 462 cultured for 8 h. After that, the medium was discarded, and the cells were labeled with

463 2 μ M calcein AM fluorescent dye (Catalog No. ab141420, Abcam) at 37°C for 20 min.

The LeicaDMI4000B inverted microscope was used to observe the capillary-like structures, and images were taken using a Leica DFC345FX camera. The number and area of the formed tubes, the number of junctions, as well as the total branching length were quantified using ImageJ software (NIH). Experiments were performed 3 468 times independently.

⁴⁶⁹**Spheroid sprouting assay**

470 As previously described, we performed the 3D sprouting assay [54]. HUVECs were ⁴⁷¹harvested after 24 h of transfection with either si-*MTDH* or si-NC to generate 472 endothelial cell spheroids. Briefly, HUVECs $(1 \times 10^3/\text{well})$ were added into 473 nonadherent round-bottom 96-well plates, and the cells spontaneously formed a single ⁴⁷⁴EC spheroid in each well within 24 h. The spheroids were then embedded in collagen ⁴⁷⁵gel and cultured for 48 h. A LeicaDMI4000B inverted microscope was used to 476 observe the spheroids after labeling with calcein AM. ImageJ software (NIH) was ⁴⁷⁷used to measure all sprouts originating from each spheroid. The cumulative sprout ⁴⁷⁸length of 10 spheroids were compared between the 2 groups. The experiments were 479 replicated 3 times independently.

⁴⁸⁰**RNA-seq and data analysis**

⁴⁸¹RNA was isolated and quality controlled. The cDNA libraries of transfected HUVECs 482 were constructed and purified, followed by sequencing on Illumina NovaSeq platform. ⁴⁸³Clean reads were achieved by processing raw data with in-house Perl scripts. HISAT2 ⁴⁸⁴was used for reads alignment and featureCounts for counting reads. DESeq2 was 485 applied for differentially expressed genes identification (adjusted $P < 0.05$). DAVID 486 v6.8 was used for gene ontology (GO) analysis. GeneMANIA was carried out to 487 construct protein-protein interaction network.

⁴⁸⁸**Statistical analysis**

⁴⁸⁹Proliferation and migration curves were estimated by two-way ANOVA using SPSS 490 software version 25.0. Paired *t*-test was applied to compare the differences between ⁴⁹¹IUGR twins and the normal cotwins. All other data comparisons were conducted with 492 Student's *t*-test. $P < 0.05$ was considered statistically significant.

⁴⁹⁴**Ethical statement**

- ⁴⁹⁵Ethical approval of our study was achieved from the Ethics Committee of the Peking
- ⁴⁹⁶University Third Hospital (IRB00006761-2016145). Prior to placental samples
- 497 collection, written informed consent was obtained from participants.

⁴⁹⁹**Data availability**

- ⁵⁰⁰The placental proteomic data of sIUGR twins have been uploaded to the iProX
- 501 database (https://www.iprox.org/) [55], and are accessible with the dataset identifier
- 502 IPX0004712000. The RNA-seq data of HUVECs have been submitted to the Genome
- 503 Sequence Archive (GSA: HRA002656) at https://ngdc.cncb.ac.cn/gsa-human/ [56].

⁵⁰⁵**Competing interests**

⁵⁰⁶All authors declare no competing interests.

507

⁵⁰⁸**Acknowledgments**

- 509 Our investigation was supported by the National Natural Science Foundation of China
- 510 (Grant Nos. 81971399 and 82171661).

511

⁵¹²**References**

- 513 [1] Romo A, Carceller R, Tobajas J. Intrauterine growth retardation (IUGR):
514 epidemiology and etiology. Pediatr Endocrinol Rev 2009;6:332–6. ⁵¹⁴epidemiology and etiology. Pediatr Endocrinol Rev 2009;6:332–6.
- 515 [2] Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth 516 mortality among very-low-birth-weight neonates with intrauterine growth restriction. Am J Obstet Gynecol 2000:182:198–206. ⁵¹⁷restriction. Am J Obstet Gynecol 2000;182:198–206.
- ⁵¹⁸[3] Barker DJ. The fetal and infant origins of adult disease. BMJ 1990;301:1111.
- 519 [4] Regnault TR, Galan HL, Parker TA, Anthony RV. Placental development in normal and compromised pregnancies-- a review. Placenta. 2002;23:S119–29. normal and compromised pregnancies-- a review. Placenta. 2002;23:S119–29.

- 521 [5] Chaddha V, Viero S, Huppertz B, Kingdom J. Developmental biology of the placenta and the origins of placental insufficiency. Semin Fetal Neonatal Med 522 placenta and the origins of placental insufficiency. Semin Fetal Neonatal Med
523 2004;9:357–69. ⁵²³2004;9:357–69.
- 524 [6] Gagnon R. Placental insufficiency and its consequences. Eur J Obstet Gynecol
525 Reprod Biol 2003:110:S99–107. ⁵²⁵Reprod Biol 2003;110:S99–107.
- 526 [7] Neerhof MG, Thaete LG. The fetal response to chronic placental insufficiency.
527 Semin Perinatol 2008;32:201–5. ⁵²⁷Semin Perinatol 2008;32:201–5.
- 528 [8] Bennasar M, Eixarch E, Martinez JM, Gratacós E. Selective intrauterine growth
529 **Exercitization** in monochorionic diamniotic twin pregnancies. Semin Fetal Neonatal 529 restriction in monochorionic diamniotic twin pregnancies. Semin Fetal Neonatal
530 Med 2017;22:376–82. Med 2017;22:376-82.
- 531 [9] Lopriore E, Pasman SA, Klumper FJ, Middeldorp JM, Walther FJ, Oepkes D.
532 Placental characteristics in growth-discordant monochorionic twins: a matched 532 Placental characteristics in growth-discordant monochorionic twins: a matched
533 case-control study. Placenta 2012:33:171-4. case-control study. Placenta 2012;33:171-4.
- ⁵³⁴[10] Kalafat E, Thilaganathan B, Papageorghiou A, Bhide A, Khalil A. Significance 535 of placental cord insertion site in twin pregnancy. Ultrasound Obstet Gynecol
536 2018;52:378–84. ⁵³⁶2018;52:378–84.
- 537 [11] Gou C, Li M, Zhang X, Liu X, Huang X, Zhou Y, et al. Placental characteristics
538 in monochorionic twins with selective intrauterine growth restriction assessed by 538 in monochorionic twins with selective intrauterine growth restriction assessed by
539 gradient angiography and three-dimensional reconstruction. J Matern Fetal 539 gradient angiography and three-dimensional reconstruction. J Matern Fetal
540 Neonatal Med 2017;30:2590–5. Neonatal Med 2017;30:2590-5.
- 541 [12] Chu S, Mao Q, Shapiro S, De Paepe ME. Placental endoglin levels in diamniotic-monochorionic twin gestations: correlation with clinical and placental 542 diamniotic-monochorionic twin gestations: correlation with clinical and placental
543 characteristics. Placenta 2013:34:261–8. ⁵⁴³characteristics. Placenta 2013;34:261–8.
- ⁵⁴⁴[13] Schrey S, Kingdom J, Baczyk D, Fitzgerald B, Keating S, Ryan G, et al. *Leptin* is 545 differentially expressed and epigenetically regulated across monochorionic twin
546 blacenta with discordant fetal growth. Mol Hum Reprod 2013:19:764–72. placenta with discordant fetal growth. Mol Hum Reprod 2013;19:764–72.
- 547 [14] Nevo O, Many A, Xu J, Kingdom J, Piccoli E, Zamudio S, et al. Placental
548 expression of soluble *fins-like tyrosine kinase 1* is increased in singletons and 548 expression of soluble *fms-like tyrosine kinase 1* is increased in singletons and
549 twin pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 549 twin pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab
550 2008:93:285–92. ⁵⁵⁰2008;93:285–92.
- ⁵⁵¹[15] Zhang GL, He ZM, Shi XM, Gou CY, Gao Y, Fang Q. Discordant *HIF1A* 552 mRNA levels and oxidative stress in placental shares of monochorionic twins
553 with selective intra-uterine growth restriction. Placenta 2015:36:297–303. with selective intra-uterine growth restriction. Placenta 2015;36:297–303.
- 554 [16] Gou C, Liu X, Shi X, Chai H, He ZM, Huang X, et al. Placental expressions of CDKNIC and KCNO10T1 in monozygotic twins with selective intrauterine 555 *CDKN1C* and *KCNQ1OT1* in monozygotic twins with selective intrauterine growth restriction. Twin Res Hum Genet 2017:20:389–94. ⁵⁵⁶growth restriction. Twin Res Hum Genet 2017;20:389–94.
- 557 [17] Roifman M, Choufani S, Turinsky AL, Drewlo S, Keating S, Brudno M, et al.
558 **Charlo Genome-wide placental DNA methylation analysis of severely growth-discordant** 558 Genome-wide placental DNA methylation analysis of severely growth-discordant
559 monochorionic twins reveals novel epigenetic targets for intrauterine growth 559 monochorionic twins reveals novel epigenetic targets for intrauterine growth
560 restriction. Clin Epigenetics 2016:8:70. restriction. Clin Epigenetics 2016;8:70.

- 561 [18] Reynolds LP, Redmer DA. Angiogenesis in the placenta. Biol Reprod $2001:64:1033-40$. ⁵⁶²2001;64:1033–40.
- 563 [19] Antfolk D, Sjoqvist M, Cheng F, Isoniemi K, Duran CL, Rivero-Muller A, et al.
564 Selective regulation of Notch ligands during angiogenesis is mediated by 564 Selective regulation of Notch ligands during angiogenesis is mediated by
565 *vimentin*. Proc Natl Acad Sci U S A 2017:114:E4574–81. ⁵⁶⁵*vimentin*. Proc Natl Acad Sci U S A 2017;114:E4574–81.
- 566 [20] Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by *ephrin-B2* and its 567 interaction between embryonic arteries and veins revealed by *ephrin-B2* and its
568 receptor *Eph-B4*. Cell 1998:93:741–53. ⁵⁶⁸receptor *Eph-B4*. Cell 1998;93:741–53.
- 569 [21] Yeh JJ, Ju R, Brdlik CM, Zhang W, Zhang Y, Matyskiela ME, et al. Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic 570 gene disruption of methionine aminopeptidase 2 results in an embryonic
571 gastrulation defect and endothelial cell growth arrest. Proc Natl Acad Sci U S A 571 gastrulation defect and endothelial cell growth arrest. Proc Natl Acad Sci U S A
572 2006;103:10379–84. ⁵⁷²2006;103:10379–84.
- ⁵⁷³[22] Liu Y, Kong X, Li X, Li B, Yang Q. Knockdown of *metadherin* inhibits ⁵⁷⁴angiogenesis in breast cancer. Int J Oncol 2015;46:2459–66.
- 575 [23] Long M, Dong K, Gao P, Wang X, Liu L, Yang S, et al. Overexpression of *astrocyte-elevated gene-1* is associated with cervical carcinoma progression and 576 astrocyte-elevated gene-1 is associated with cervical carcinoma progression and
577 approximation angular contract and angular contract angular contract angular contract angular contract angular contract angular contra ⁵⁷⁷angiogenesis. Oncol Rep 2013;30:1414–22.
- 578 [24] Whitehead CL, Walker SP, Ye L, Mendis S, Kaitu'u-Lino TJ, Lappas M, et al.
579 Placental specific mRNA in the maternal circulation are globally dysregulated in 579 Placental specific mRNA in the maternal circulation are globally dysregulated in
580 pregnancies complicated by fetal growth restriction. J Clin Endocrinol Metab 580 pregnancies complicated by fetal growth restriction. J Clin Endocrinol Metab
581 2013:98:E429–36. 2013;98:E429-36.
- 582 [25] McMinn J, Wei M, Schupf N, Cusmai J, Johnson EB, Smith AC, et al.
583 Unbalanced placental expression of imprinted genes in human intrauterine 583 Unbalanced placental expression of imprinted genes in human intrauterine
584 growth restriction. Placenta 2006:27:540-9. ⁵⁸⁴growth restriction. Placenta 2006;27:540–9.
- ⁵⁸⁵[26] Sferruzzi-Perri AN, Macpherson AM, Roberts CT, Robertson SA. *Csf2* null 586 mutation alters placental gene expression and trophoblast glycogen cell and giant cell abundance in *mice*. Biol Reprod 2009:81:207-21. ⁵⁸⁷cell abundance in *mice*. Biol Reprod 2009;81:207–21.
- 588 [27] Robertson SA, Roberts CT, Farr KL, Dunn AR, Seamark RF. Fertility
589 impairment in granulocyte-macrophage colony-stimulating factor-deficient *mice*. 589 impairment in granulocyte-macrophage colony-stimulating factor-deficient *mice*.
590 Biol Reprod 1999:60:251–61. Biol Reprod 1999;60:251–61.
- 591 [28] Lambertini L, Li Q, Ma Y, Zhang W, Hao K, Marsit C, et al. Placental imprinted
592 sene expression mediates the effects of maternal psychosocial stress during 592 gene expression mediates the effects of maternal psychosocial stress during
593 pregnancy on fetal growth. J Dev Orig Health Dis 2019:10:196–205. ⁵⁹³pregnancy on fetal growth. J Dev Orig Health Dis 2019;10:196–205.
- 594 [29] Chen X, Bai G, Scholl TO. Spontaneous preterm delivery, particularly with reduced fetal growth, is associated with DNA hypomethylation of tumor related 595 reduced fetal growth, is associated with DNA hypomethylation of tumor related
596 genes. J Pregnancy Child Health 2016:3:215. genes. J Pregnancy Child Health 2016;3:215.
- 597 [30] Matsuda M, Tsutsumi K, Kanematsu T, Fukami K, Terada Y, Takenawa T, et al.
598 Involvement of phospholipase C-related inactive protein in the mouse 598 Involvement of phospholipase C-related inactive protein in the mouse
599 reproductive system through the regulation of gonadotropin levels. Biol Reprod 599 reproductive system through the regulation of gonadotropin levels. Biol Reprod
600 2009:81:681-9. ⁶⁰⁰2009;81:681–9.

- 601 [31] Audette MC, Kingdom JC. Screening for fetal growth restriction and placental 602 insufficiency. Semin Fetal Neonatal Med 2018:23:119–25. insufficiency. Semin Fetal Neonatal Med 2018;23:119–25.
- 603 [32] Li W, Chung CYL, Wang CC, Chan TF, Leung MBW, Chan OK, et al.
604 Monochorionic twins with selective fetal growth restriction: insight from 604 Monochorionic twins with selective fetal growth restriction: insight from
605 placental whole-transcriptome analysis. Am J Obstet Gynecol 605 placental whole-transcriptome
606 2020:223:749.e1-16. 2020;223:749.e1-16.
- 607 [33] Li X, Wang W, Chen J. Recent progress in mass spectrometry proteomics for biomedical research. Sci China Life Sci 2017:60:1093–113. biomedical research. Sci China Life Sci 2017;60:1093-113.
- 609 [34] Maltepe E, Fisher SJ. Placenta: the forgotten organ. Annu Rev Cell Dev Biol
610 2015:31:523–52. ⁶¹⁰2015;31:523–52.
- 611 [35] Herrera E, Ortega-Senovilla H. Lipid metabolism during pregnancy and its
612 implications for fetal growth. Curr Pharm Biotechnol 2014:15:24–31. implications for fetal growth. Curr Pharm Biotechnol 2014;15:24–31.
- 613 [36] Chabrun F, Huetz N, Dieu X, Rousseau G, Bouzille G, Chao de la Barca JM, et al. Data-mining approach on transcriptomics and methylomics placental analysis 614 al. Data-mining approach on transcriptomics and methylomics placental analysis
615 highlights genes in fetal growth restriction. Front Genet 2019:10:1292. highlights genes in fetal growth restriction. Front Genet 2019;10:1292.
- 616 [37] Paules C, Youssef L, Miranda J, Crovetto F, Estanyol JM, Fernandez G, et al.
617 Maternal proteomic profiling reveals alterations in lipid metabolism in late-onset 617 Maternal proteomic profiling reveals alterations in lipid metabolism in late-onset
618 fetal growth restriction. Sci Rep 2020:10:21033. fetal growth restriction. Sci Rep $2020;10:21033$.
- 619 [38] Zur RL, Kingdom JC, Parks WT, Hobson SR. The placental basis of fetal growth restriction. Obstet Gynecol Clin North Am 2020:47:81–98. restriction. Obstet Gynecol Clin North Am 2020;47:81-98.
- 621 [39] Chassen S, Jansson T. Complex, coordinated and highly regulated changes in placental signaling and nutrient transport capacity in IUGR. Biochim Biophys 622 placental signaling and nutrient transport capacity in IUGR. Biochim Biophys
623 Acta Mol Basis Dis 2020:1866:165373. Acta Mol Basis Dis 2020;1866:165373.
- 624 [40] Huppertz B, Peeters LL. Vascular biology in implantation and placentation.
625 Angiogenesis 2005:8:157–67. Angiogenesis 2005;8:157–67.
- 626 [41] Mayhew TM, Charnock-Jones DS, Kaufmann P. Aspects of human fetoplacental
627 **Startus Convenents and angiogenesis. III.** Changes in complicated pregnancies. 627 vasculogenesis and angiogenesis. III. Changes in complicated pregnancies.
628 Placenta 2004:25:127–39. Placenta 2004;25:127-39.
- 629 [42] Chen CP, Bajoria R, Aplin JD. Decreased vascularization and cell proliferation
630 **in** placentas of intrauterine growth-restricted fetuses with abnormal umbilical 630 in placentas of intrauterine growth-restricted fetuses with abnormal umbilical
631 artery flow velocity waveforms. Am J Obstet Gynecol 2002;187:764–9. artery flow velocity waveforms. Am J Obstet Gynecol 2002;187:764–9.
- ⁶³²[43] Manna D, Sarkar D. Multifunctional role of *astrocyte elevated gene-1* (*AEG-1*) in cancer: focus on drug resistance. Cancers (Basel) 2021;13.
- 634 [44] Dhiman G, Srivastava N, Goyal M, Rakha E, Lothion-Roy J, Mongan NP, et al.
635 Metadherin: a therapeutic target in multiple cancers. Front Oncol 2019;9:349. Metadherin: a therapeutic target in multiple cancers. Front Oncol 2019;9:349.
- 636 [45] Melamed N, Baschat A, Yinon Y, Athanasiadis A, Mecacci F, Figueras F, et al.
637 **FIGO** (international federation of gynecology and obstetrics) initiative on fetal FIGO (international federation of gynecology and obstetrics) initiative on fetal
638 serve the set practice advice for screening, diagnosis, and management of fetal 638 growth: best practice advice for screening, diagnosis, and management of fetal
639 growth restriction. Int J Gynaecol Obstet 2021:152:3–57. growth restriction. Int J Gynaecol Obstet 2021;152:3–57.

- 640 [46] Smith GCS. Universal screening for foetal growth restriction. Best Pract Res
641 Clin Obstet Gynaecol 2018:49:16–28. ⁶⁴¹Clin Obstet Gynaecol 2018;49:16–28.
- 642 [47] Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal
643 veright with the use of head, body, and femur measurements a prospective-study. 643 weight with the use of head, body, and femur measurements - a prospective-study.
644 Am J Obstet Gynecol 1985:151:333–7. Am J Obstet Gynecol 1985;151:333–7.
- 645 [48] Wyatt SM, Kraus FT, Roh CR, Elchalal U, Nelson DM, Sadovsky Y. The correlation between sampling site and gene expression in the term human 646 correlation between sampling site and gene expression in the term human placenta. Placenta 2005:26:372-9. ⁶⁴⁷placenta. Placenta 2005;26:372–9.
- 648 [49] Sood R, Zehnder JL, Druzin ML, Brown PO. Gene expression patterns in human placenta. Proc Natl Acad Sci U S A 2006;103:5478–83. ⁶⁴⁹placenta. Proc Natl Acad Sci U S A 2006;103:5478–83.
- 650 [50] Cox J, Mann M. MaxQuant enables high peptide identification rates,
651 individualized p.p.b.-range mass accuracies and proteome-wide protein 651 individualized p.p.b.-range mass accuracies and proteome-wide protein
652 quantification. Nat Biotechnol 2008:26:1367–72. quantification. Nat Biotechnol 2008;26:1367–72.
- 653 [51] Magrane M. UniProt knowledgebase: a hub of integrated protein data. Database
654 (Oxford) 2011:2011:bar009. ⁶⁵⁴(Oxford) 2011;2011:bar009.
- 655 [52] Zhou T, Li C, Zhao W, Wang X, Wang F, Sha J. MaxReport: An enhanced proteomic result reporting tool for MaxQuant. PLoS One 2016:11:e0152067. proteomic result reporting tool for MaxQuant. PLoS One 2016;11:e0152067.
- 657 [53] Deutsch EW, Mendoza L, Shteynberg D, Farrah T, Lam H, Tasman N, et al. A
658 guided tour of the Trans-Proteomic Pipeline. Proteomics 2010;10:1150–9. guided tour of the Trans-Proteomic Pipeline. Proteomics 2010;10:1150–9.
- ⁶⁵⁹[54] Cattaneo MG, Lucci G, Vicentini LM. Oxytocin stimulates *in vitro* angiogenesis via a Pyk-2/Src-dependent mechanism. Exp Cell Res 2009;315:3210–9.
- 661 [55] Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. iProX: an integrated proteome resource. Nucleic Acids Res 2019:47:D1211-7. resource. Nucleic Acids Res 2019;47:D1211–7.
- 663 [56] Chen T, Chen X, Zhang S, Zhu J, Tang B, Wang A, et al. The genome sequence archive family: toward explosive data growth and diverse data types. Genomics 664 archive family: toward explosive data growth and diverse data types. Genomics
665 Proteomics Bioinformatics 2021:19:578–83. Proteomics Bioinformatics 2021;19:578–83.
-

Figure Legends

Figure 1 Identification and biofunction analysis of DEPs in IUGR twin placentas

A. Proteomic workflow for placental tissues from normal cotwins and IUGR twins. Twelve samples from 6 sIUGR pregnancies were enrolled in this study and labeled 672 with two sets of six-plex TMT reagents. **B.** Histogram plot showing the $log_2 FC$ distribution of all identified proteins. **C.** Volcano plot of DEPs between IUGR twin 674 placentas and normal cotwin placentas. DEPs were selected with $P < 0.05$ and $|FC| > 0.05$ 1.3. Red spots indicate the downregulated DEPs, blue spots represent the upregulated DEPs, and gray spots indicate proteins without significantly different expression. **D.** Heatmap of the DEPs identified in IUGR twin placentas. Proteins are represented by 678 rows, and samples by columns. **E.** Functional analysis of the DEPs in IUGR twin 679 placentas using IPA software. DEPs, differentially expressed proteins; IUGR, 680 intrauterine growth restriction; sIUGR, selective IUGR; RPLC, reverse-phase liquid 681 chromatography; FC, fold change; LC-MS/MS, liquid chromatography tandem mass 682 spectrometry; N, normal cotwin; I, IUGR twin; TMT, tandem mass tag; IPA, 683 ingenuity pathway analysis.

Figure 2 Impairment of angiogenesis in IUGR twin placentas

A. IPA identified the "angiogenesis" annotation to be affected in IUGR twin placentas. **B.** Immunostaining of CD34 in human placentas from IUGR twins and normal cotwins. CD34 is limited to endothelial cells. Scale bar, 50 μm. **C.** Placental MVD in IUGR twins and normal cotwins. **D.** Placental vascular area density in IUGR twins and normal cotwins. **E.** Immunohistochemical images of EFNB2, VIM, and METAP2 in placental shares from IUGR twins and normal cotwins. Scale bar, 100 μm. **F**–**H.** EFNB2, VIM, and METAP2 immunostaining intensity per tissue area is represented by the fold-decrease relative to the normal control mean. **I**–**K.** qRT-PCR analysis showed that the *EFNB2*, *VIM*, and *METAP2* transcriptional levels were significantly lower in placentas of IUGR twins compared with normal cotwins. All data are shown

- 696 as mean \pm SD with 6 samples per group. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$.
- MVD, microvessel density; NC, negative control; SD, standard deviation.
-

Figure 3 *MTDH* **expression is downregulated in IUGR twin placentas, and**

MTDH **knockdown impairs HUVECs proliferation and migration**

- 701 **A.** *MTDH* mRNA levels in IUGR twin placentas ($n = 6$) and normal cotwin placentas (n = 6) by qRT-PCR analysis. **B.** MTDH expression in placental shares of IUGR twins and normal cotwins by immunohistochemistry. Scale bar, 100 μm. **C.** MTDH immunostaining intensity in IUGR twin and normal cotwin placentas (n = 6 in each group). **D**–**F.** After transfection for 48 h, the interference efficiency of siRNA 706 targeting *MTDH* in HUVECs was evaluated by qRT-PCR (**D**) and western blotting (**E**). The relative intensity of MTDH levels was evaluated by ImageJ from three 708 independent experiments (**F**). **G.** Proliferation curves showed that *MTDH* knockdown 709 greatly inhibited HUVECs proliferation. Two-way ANOVA was used for data analysis. **H.** Migration curves revealed that *MTDH* knockdown greatly inhibited HUVECs migration. Two-way ANOVA was used for data analysis. **I**–**J.** Knockdown of *MTDH* in HUVECs decreased the rate of wound closure. Scale bar, 100 μm. All experiments 713 had 3 replicates with results shown as mean \pm SD. *, $P < 0.05$; **, $P < 0.01$; ***, $P <$ 714 0.001. ANOVA, analysis of variance.
-

Figure 4 *MTDH* **knockdown inhibits HUVECs tube formation and spheroid sprouting**

A. HUVECs were harvested 48 h after transfection with si-NC or si-*MTDH* and then 719 plated in Matrigel-coated wells. After 8 h, HUVEC tube formation was observed under a LeicaDMI4000B microscope and photographed. Scale bar, 100 μm. **B**–**E.** Quantification of the number of tubes (\mathbf{B}) , total tube length (\mathbf{C}) , total tube area (\mathbf{D}) , 722 and number of branching points (E) in the si-*MTDH* group and the si-NC group using ImageJ software. The results were from three independent assays. **F.** si-NC or si-*MTDH* transfected HUVECs spheroids were photographed 48 h later after embedding in collagen gels. Scale bar, 100 μm. **G.** ImageJ software was used to

- 726 quantify the cumulative sprout length in the si-*MTDH* group and the si-NC group. All
- 727 data are expressed as mean \pm SD from 3 experiments. **, $P < 0.01$; ***, $P < 0.001$.
- 728

⁷²⁹**Figure 5 RNA-seq analysis of HUVECs following** *MTDH* **interference**

A. Correlation coefficient analysis based on RNA-seq data for each sample pair. Three replicates per condition. **B.** Heatmap of the top 50 differentially expressed 732 protein-coding genes between si-*MTDH* group and si-NC group. Genes are represented by rows, and samples by columns. **C.** Bubble plot depicting biological process enrichment for 50 candidates by gene ontology. **D.** Interaction network of the 50 candidate genes. The network was constructed by GeneMANIA and visualized 736 using Cytoscape 3.7.2.

737

739

⁷⁴⁰**Supplementary material**

⁷⁴¹**Figure S1 Clinical characteristics and placental histopathology of sIUGR twins**

⁷⁴²**A**–**B.** Representative images of ultrasound biometric measurements of the normal 743 cotwin (A) and the IUGR twin (B) from a sIUGR pregnancy, including BPD, HC, AC, ⁷⁴⁴and FL. **C.** Ultrasound estimated fetal weight of the normal cotwins and the IUGR 745 twins from six pairs of sIUGR pregnancies throughout gestation were plotted on the 746 fetal growth curve. **D.** Birth weight of the normal cotwins and the IUGR twins ($n = 6$) 747 in each group). **E.** Normal placental parenchyma from the normal cotwin. Scale bar, ⁷⁴⁸100 μm. **F.** Distal villous hypoplasia in the IUGR twin placenta. Scale bar, 100 μm. **G.** ⁷⁴⁹Increased fibrin deposition (arrow) in the IUGR twin placenta. Scale bar, 100 μm. **H.** ⁷⁵⁰Increased syncytial knots (arrow) in the IUGR twin placenta. Scale bar, 100 μm. **I.** ^A 751 representative image of sIUGR twin placenta after dye injection. Placental sharing ⁷⁵²was indicated by the white dotted line. Velamentous cord insertion was observed in 753 the IUGR twin. ***, $P < 0.001$. BPD, biparietal diameter; HC, head circumference; 754 AC, abdominal circumference; FL, femur length.

Physiological system development and function

 A

3 -

 $2 -$

l 1

3

 $\overline{2}$

1 ä,

B

1

զ

Կ

Ł

HCLIN-is

Si-NC